Table 1.
Characteristics of Eligible Studies in a Systematic Review of TP53 rs1042522 and 5 Common Epithelial Cancers (n = 160)
| Study Characteristic | Breast Cancer (68 Studies) |
Lung Cancer (42 Studies) |
Colorectal Cancer (26 Studies) |
Ovarian Cancer (16 Studies) |
Endometrial Cancer (8 Studies) |
All Studies (160 Studies) |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. | % of Studiesa | No. | % of Studies | No. | % of Studies | No. | % of Studies | No. | % of Studies | No. | % of Studies | |
| No. of cases | 30,586 | 16,743 | 7,377 | 1,982 | 726 | 57,414 | ||||||
| No. of controls | 36,213 | 16,504 | 10,011 | 5,226 | 1,292 | 69,246 | ||||||
| Median no. of cases (IQR) | 166 (94–436) | 147 (91–307) | 121 (76–345) | 109 (48–193) | 94 (43–118) | 137 (78–293) | ||||||
| Median no. of controls (IQR) | 215 (109–486) | 176 (133–379) | 220 (140–347) | 281 (74–446) | 78 (31–310) | 209 (109–423) | ||||||
| Ethnicity | ||||||||||||
| White | 45 | 66 | 16 | 38 | 16 | 62 | 13 | 81 | 6 | 75 | 96 | 60 |
| East Asian | 10 | 15 | 13 | 31 | 8 | 31 | 2 | 13 | 2 | 25 | 35 | 22 |
| Black | 1 | 1 | 2 | 5 | 0 | 0 | 1 | 6 | 0 | 0 | 4 | 3 |
| Latino | 1 | 1 | 3 | 7 | 1 | 4 | 0 | 0 | 0 | 0 | 5 | 3 |
| Other/mixed/NR | 11 | 16 | 8 | 19 | 1 | 4 | 0 | 0 | 0 | 0 | 20 | 13 |
| Control selection | ||||||||||||
| Healthy | 61 | 90 | 24 | 57 | 19 | 73 | 15 | 94 | 6 | 75 | 125 | 78 |
| Diseased | 7 | 10 | 18 | 43 | 7 | 27 | 1 | 6 | 2 | 25 | 35 | 22 |
| Matched controls | ||||||||||||
| Yes | 29 | 43 | 22 | 52 | 10 | 38 | 6 | 37 | 2 | 25 | 69 | 43 |
| No/not applicable | 39 | 57 | 20 | 48 | 16 | 62 | 10 | 63 | 6 | 75 | 91 | 57 |
| Blinding to case-control status | ||||||||||||
| Yes | 7 | 10 | 9 | 21 | 3 | 12 | 2 | 12 | 0 | 0 | 21 | 13 |
| No/NR | 61 | 90 | 33 | 79 | 23 | 88 | 14 | 88 | 8 | 100 | 139 | 87 |
| Use of genotyping quality control | ||||||||||||
| Yes | 26 | 38 | 17 | 40 | 11 | 42 | 9 | 56 | 2 | 25 | 65 | 41 |
| No/NR | 42 | 62 | 25 | 60 | 15 | 57 | 7 | 44 | 6 | 75 | 95 | 59 |
| Genotyping methods | ||||||||||||
| RFLP | 32 | 47 | 24 | 57 | 13 | 50 | 2 | 12 | 3 | 38 | 74 | 46 |
| Other methods | 36 | 53 | 18 | 43 | 13 | 50 | 14 | 88 | 5 | 63 | 86 | 54 |
| Hardy-Weinberg equilibrium | ||||||||||||
| Compliant | 53 | 78 | 36 | 86 | 24 | 92 | 13 | 81 | 7 | 88 | 133 | 83 |
| In violation | 15 | 22 | 6 | 14 | 2 | 8 | 3 | 19 | 1 | 12 | 27 | 17 |
| Use of only tumor tissue for genotypingb | ||||||||||||
| Yes | 9 | 13 | 3 | 7 | 6 | 23 | 2 | 12 | 2 | 25 | 22 | 14 |
| No | 59 | 87 | 39 | 93 | 20 | 77 | 14 | 88 | 6 | 75 | 138 | 86 |
Abbreviations: IQR, interquartile range; NR, not reported; RFLP, restriction fragment length polymorphism.
a Percentages have been rounded to the nearest integer. Percentages might not sum to 100 because of rounding.
b In all cases, studies provided adequate data to evaluate the source of DNA for case genotyping.